Value Partners Group led a $34m Series A round in Phase Scientific.

Value Partners Group, a financial services firm including investment management, advisory, and asset allocation services, led a $34m Series A round in Phase Scientific, a pioneering biotechnology company revolutionizing early disease detection through proprietary urine-based diagnostics. "The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection. With this capital, we will accelerate R&D and commercialization efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market. Our mission is to empower millions worldwide with non-invasive, user-friendly testing that can save lives through earlier intervention," Dr. Ricky Chiu, PHASE Scientific Founder, Chairman and CEO.